Akums Drugs & Pharmaceuticals Ltd
Healthcare | Small Cap
Akums Drugs & Pharmaceuticals Ltd showcases a dual financial profile. On one hand, the company demonstrates exceptional financial stability, characterized by extremely low debt levels and a balance sheet heavily funded by equity. This minimizes financial risk. Profitability is another key strength, with strong margins and high returns on both equity and capital employed. However, this is contrasted by significant operational weaknesses. The company is inefficient in using its assets and capital to generate sales, and it takes a considerable time to sell inventory and collect payments from customers. Growth has been volatile, with strong revenue and asset expansion but accompanied by severely negative earnings per share growth historically. Projections point towards a significant improvement in liquidity and income, but this hinges on turning its large asset base into efficient and stable profits.
Latest Report
View AllThe Latest Reports Are Not Available at the Moment. We’ll Notify You Once They’re Available.
Latest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsOvervalued
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio8.00
- Financial Ratio6.60
- Profitability Ratio9.80
- Efficiency Ratio4.33
- Coverage Ratio8.40
- Solvency Ratio10.00
- Liquidity Ratio6.70
- Peer Assessment
- Management AssessmentBalanced
- Risk AssessmentWeak
- 1 HourBullish
- 2 HoursBullish
- 4 HoursBullish
- 1 DayBullish
- 1 WeekBullish
- 1 MonthNeutral
Akums Drugs & Pharmaceuticals Ltd showcases a dual financial profile. On one hand, the company demonstrates exceptional financial stability, characterized by extremely low debt levels and a balance sheet heavily funded by equity. This minimizes financial risk. Profitability is another key strength, with strong margins and high returns on both equity and capital employed. However, this is contrasted by significant operational weaknesses. The company is inefficient in using its assets and capital to generate sales, and it takes a considerable time to sell inventory and collect payments from customers. Growth has been volatile, with strong revenue and asset expansion but accompanied by severely negative earnings per share growth historically. Projections point towards a significant improvement in liquidity and income, but this hinges on turning its large asset base into efficient and stable profits.
Overall Valuation Score
P/E RATIO (TTM)
84.87
Industry Median
28.93
Small Cap Median
26.92
P/E RATIO
37.12
P/B RATIO
2.85
Industry Median
3.18
Small Cap Median
2.63
P/S RATIO
2.17
Industry Median
3.41
Small Cap Median
2.40
Others
PEG RATIO
2.36
EV/EBITDA RATIO
12.44
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹601.7 as on Jun 18, 2026.
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
The company's growth profile is marked by extreme volatility and contrasts. On the positive side, it is expanding its asset base aggressively and shows strong revenue growth potential, with projections indicating a powerful recovery in operating profit. However, this is severely undermined by a very poor and erratic performance in earnings per share (EPS). The negative EPS growth is a significant red flag for shareholder value creation. This disparity suggests that while the company is getting bigger, this expansion has not translated into stable, profitable growth for its owners.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 34.85 | -0.46 | 14.31 | -1.44 | 5.85 |
| Operating Profit Growth Rate | -137.39 | -430.34 | -58.16 | 278.05 | 12.26 |
| Earnings Per Share (EPS) Growth | -103.74 | -118.78 | -104.22 | -7775 | -24.57 |
| Asset Growth Rate | 41.73 | 6.26 | 8.11 | 16.87 | 33.02 |
| Net Income Growth Rate | -304.07 | -139.04 | -98.98 | 34300 | -25.58 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
The company's financial metrics present a mixed view. Positives include strong cash earnings per share and a very high book value, suggesting underlying substance and cash-generating ability. However, shareholder returns in the form of dividends have been nonexistent historically and are projected to be modest. A significant negative is the very high level of capital expenditures, which, while indicating investment for the future, acts as a major drain on cash resources. The adjusted earnings per share level is good, but this contrasts with its poor growth history.
| Financial Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | -34.29 | 9.17 | -0.76 | 21.55 | 17.42 |
| Cash Earnings Per Share (Cash EPS) | -22.29 | 14.55 | 8.76 | 32.06 | 26.52 |
| Book Value Per Share | 88.86 | 49.52 | 48.97 | 196.58 | 213.81 |
| Dividend Per Share (DPS) | 0 | 0 | 0 | 0 | 2.92 |
| Capital Expenditures (CapEx) | 256 | 287 | 286 | 263 | 223 |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
The company's profitability is a standout strength across nearly all measures. It demonstrates an excellent ability to generate profit from its sales, as seen in its strong margins from the gross to the net level. Furthermore, it produces high returns on the capital invested by both shareholders and lenders (ROCE) and on the equity invested by its owners (ROE). This indicates that the core business is fundamentally very profitable and efficient at turning revenue into actual profit. This strong performance provides a solid financial cushion and supports long-term value creation.
| Profitability Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Profit Margin | -5.01 | 4.95 | -0.07 | 7.58 | 8.42 |
| Return on Capital Employed (ROCE) | -16 | 22 | 2 | 16 | 15 |
| Return on Equity (ROE) | -40.35 | 13.65 | 0.14 | 11.29 | 7.72 |
| Return on Assets (ROA) | -2.92 | 9.07 | 3.51 | 11.36 | 9.58 |
| Operating Margin | -2.42 | 8.04 | 2.94 | 11.29 | 11.98 |
| Net Margin | -6.84 | 2.68 | 0.02 | 8.35 | 5.87 |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
The company's operational efficiency is a notable area of concern. The data shows a consistent pattern of underperformance in generating sales from its asset and capital base. It takes the company a relatively long time to sell its inventory and to collect cash from its customers after a sale is made. This indicates that working capital is tied up for extended periods. This combination of slow-moving inventory and delayed collections points to challenges in the company's core operational cycle, from production to cash realization.
| Efficiency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Fixed Asset Turnover Ratio | 3.6 | 3.33 | 3.51 | 2.95 | 2.99 |
| Inventory Turnover Ratio | 6.69 | 4.79 | 6.15 | 5.81 | 5.56 |
| Receivables Turnover Ratio | 5.19 | 4.23 | 4.98 | 5.13 | 5.56 |
| Days Sales in Inventory Ratio | 54.56 | 76.2 | 59.35 | 62.82 | 65.65 |
| Receivable Days | 70.33 | 86.29 | 73.29 | 71.15 | 65.65 |
| Capital Turnover Ratio | 5.46 | 3.99 | 4.85 | 1.32 | 1.28 |
Fixed Asset Turnover Ratio
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
Capital Turnover Ratio
The company's ability to cover its financial obligations is strong overall. Its capacity to meet interest payments on its debt is excellent, which is a direct result of its very low reliance on borrowing. This provides a substantial safety margin and insulates it from interest rate risk. The ability to cover future planned dividend payments from its earnings is adequate. This indicates that while the company can comfortably service its debt, its planned shareholder payouts are reasonably, but not excessively, covered by profits.
| Coverage Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Interest Coverage Ratio | -10.35 | 4.26 | 0.12 | 10.86 | 5.06 |
| Equity Dividend Coverage Ratio | 5.56 |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
The company's solvency is exceptionally strong, representing a key pillar of its financial health. All related metrics indicate an extremely low reliance on debt to finance its assets. The vast majority of its funding comes from equity, which signifies a very conservative financial structure and minimal risk to creditors. This position means the company is well-insulated from risks associated with rising interest rates and has significant borrowing capacity if needed for future expansion. It is a hallmark of outstanding long-term financial stability.
| Solvency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debt Ratio | 0.07 | 0.22 | 0.18 | 0.02 | 0.02 |
| Debt to Equity Ratio | 0.08 | 0.28 | 0.22 | 0.02 | 0.02 |
| Equity Ratio | 0.93 | 0.78 | 0.82 | 0.98 | 0.98 |
| Debt To Asset Ratio | 0.02 | 0.06 | 0.04 | 0.02 | 0.02 |
Debt Ratio
Debt to Equity Ratio
Equity Ratio
Debt To Asset Ratio
The company's liquidity position presents a mixed but improving picture. It has a good ability to cover its short-term obligations with its current and quick assets, suggesting that inventory is not a major impediment. The amount of cash on hand to meet immediate debts is also healthy. A key concern is its weaker capacity to cover liabilities using cash generated from its core operations. However, forward-looking data indicates a substantial projected improvement in all liquidity metrics, pointing towards a much stronger ability to meet short-term financial needs in the near future.
| Liquidity Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Current Ratio | 0.84 | 0.88 | 0.8 | 2.6 | 1.86 |
| Quick Ratio | 0.54 | 0.56 | 0.56 | 1.9 | 1.49 |
| Cash Ratio | 0.04 | 0.06 | 0.1 | 0.59 | 0.82 |
| Operating Cash Flow Ratio | 0.01 | 0.08 | 0.19 | 0.48 | 0.58 |
Current Ratios
Quick Ratios
Cash Ratios
Operating Cash Flow Ratios
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | FDC Ltd | 7.64 | 22.22 | Neutral | 346.00 | 17.56 | 281.00 |
| 2 | Supriya Lifescience Ltd | 7.46 | 35.88 | Highly Overvalued | 294.00 | 25.98 | 209.00 |
| 3 | Aarti Pharmalabs Ltd | 7.46 | 34.17 | Neutral | 369.00 | 19.44 | 175.00 |
| 4 | Innova Captab Ltd | 7.36 | 37.88 | Overvalued | 243.00 | 14.63 | 141.00 |
| 5 | Akums Drugs & Pharmaceuticals Ltd | 7.28 | 37.12 | Overvalued | 522.00 | 7.09 | 256.00 |
| 6 | Marksans Pharma Ltd | 7.24 | 28.36 | Neutral | 601.00 | 6.64 | 420.00 |
| 7 | Hikal Ltd | 7.13 | -50.15 | Neutral | 220.00 | -3.95 | -49.00 |
| 8 | RPG Life Sciences Ltd | 7.12 | 32.71 | Neutral | 147.00 | 69.64 | 115.00 |
| 9 | SMS Pharmaceuticals Ltd | 5.94 | 34.36 | Neutral | 171.00 | 9.35 | 102.00 |
| 10 | Shilpa Medicare Ltd | 5.94 | 43.86 | Highly Overvalued | 435.00 | 6.80 | 243.00 |
| 11 | Strides Pharma Science Ltd | 5.55 | 18.41 | Undervalued | 925.00 | 19.92 | 575.00 |
| 12 | Jeena Sikho Lifecare Ltd | 5.52 | 30.78 | Neutral | 349.00 | 17.87 | 222.00 |
| 13 | Gufic BioSciences Ltd | 5.49 | 55.88 | Neutral | 151.00 | 6.30 | 64.00 |
| 14 | Dishman Carbogen Amcis Ltd | 5.38 | 27.35 | Neutral | 566.00 | -2.45 | 97.00 |
| 15 | Aarti Drugs Ltd | 5.07 | 17.33 | Undervalued | 309.00 | 18.54 | 195.00 |
| 16 | Orchid Pharma Ltd | 4.85 | 248.95 | Neutral | 41.00 | 8.91 | 21.00 |
| 17 | Sequent Scientific Ltd | 4.61 | 291.78 | Overvalued | 162.00 | 0.63 | 32.00 |
| 18 | Sun Pharma Advanced Research Company Ltd | 4.35 | 5.07 | Neutral | 1599.00 | 47.83 | 1553.00 |
| 19 | Zota Health Care Ltd | 3.97 | -59.69 | Neutral | 19.00 | 8.06 | -74.00 |
| 20 | Procter & Gamble Health Ltd | 3.45 | 32.04 | Neutral | 457.00 | 196.94 | 327.00 |
| 21 | Sanofi India Ltd | 3.45 | 18.76 | Neutral | 491.00 | 134.52 | 413.00 |
Management effectiveness presents a mixed picture. Key strengths include a very high and stable promoter holding, indicating strong alignment and long-term commitment. This is further supported by a significant increase in DII shareholding, suggesting growing domestic institutional confidence. However, these positives are heavily counterbalanced by severe weaknesses in financial execution. The company exhibits extreme volatility in profitability, with net profits swinging from large gains to significant losses. Recent capital efficiency metrics like ROCE and ROE are poor, indicating unproductive use of capital. The consistent lack of dividend payouts and declining FII interest are additional points of concern, reflecting a potential disconnect with certain shareholder expectations and waning confidence from foreign investors.
| Category | Metric | Value | Assessment |
|---|---|---|---|
| PROS | High Promoter Holding | 75.26% | Very Strong |
| Increasing DII Holding | 14.36% (Mar'26) | Strong | |
| CONS | Volatile Profitability | TTM Profit Growth: -17% | Volatile |
| Poor Capital Efficiency | ROCE (TTM): 2% | Poor | |
| Declining FII Holding | 1.38% (Mar'26) | Declining | |
| No Dividend Payout | 0% | Weak |
Financial Performance & Growth
The company's financial performance is characterized by significant instability and weakness, particularly in profitability. While compounded sales growth has been moderate, recent performance (TTM: 14.32%) is offset by extreme profit volatility. Compounded profit growth figures are misleading due to a low base and erratic annual performance, with TTM profit growth negative at -17%. Annual net profit has fluctuated wildly, from a profit of ₹123 Cr in 2021 to a loss of ₹251 Cr in 2022, followed by a recovery to ₹98 Cr in 2023 and a sharp drop to just ₹1 Cr in 2024. This inconsistency is also reflected in the Operating Profit Margin (OPM), which has been unstable and low in recent years, indicating a lack of control over operational efficiency. The quarterly results further confirm this pattern of erratic sales and profit figures, making financial performance unpredictable.
| Metric (₹ Cr) | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| Net Profit | 123 | -251 | 98 | 1 |
| OPM (%) | 9% | -2% | 8% | 3% |
Capital Efficiency & Returns
Capital efficiency and returns are poor and highly inconsistent. The Return on Capital Employed (ROCE) has been extremely volatile, swinging from a respectable 20% in 2021 to a negative -16% in 2022, before rebounding to 22% in 2023 and then collapsing to a mere 2% in the latest year (Mar 2024). This demonstrates an unreliable ability to generate profits from capital invested in the business. Similarly, the Return on Equity (ROE) for the last year stands at 8%, which is a weak return for shareholders. Although the 3-year average ROE is 10%, this is skewed by past performance and does not reflect the current poor state. The Cash Conversion Cycle, while improving in the most recent year to 87 days, has historically been high, indicating periods of inefficient working capital management. The overall picture suggests the management has struggled to deploy capital effectively and consistently.
| Metric (%) | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| ROCE | 20% | -16% | 22% | 2% |
| ROE (LY) | 8% |
Financial Health & Prudence
The company's financial health shows signs of weakness. Borrowings increased significantly to ₹619 Cr in Mar 2023 before a slight reduction to ₹565 Cr in Mar 2024, indicating a reliance on debt. The Interest Coverage Ratio, a key measure of the ability to service debt, has deteriorated. It stood at 6.4x in Mar 2023 but fell to a low 2.4x in Mar 2024. This low ratio indicates a reduced buffer to cover interest payments from operational earnings. Furthermore, the company has a consistent policy of a 0% dividend payout. While this can imply reinvestment for growth, the poor and volatile returns on capital suggest that these retained earnings are not being used effectively to create shareholder value. The combination of notable debt, a weak interest coverage ratio, and no profit sharing with shareholders points to a weak financial prudence framework.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|
| Borrowings (₹ Cr) | 395 | 619 | 565 |
| Interest Coverage Ratio | -5.2x | 6.4x | 2.4x |
| Dividend Payout (%) | 0% | 0% | 0% |
Shareholding & Ownership Structure
The ownership structure is a key strength. Promoter holding is very high and has remained stable at 75.26%, which signals strong confidence and long-term commitment from the management. Another significant positive is the trend in Domestic Institutional Investor (DII) holding. DIIs have substantially increased their stake, with their holding growing from 7.39% to 14.36% over the period shown. This indicates rising confidence from sophisticated domestic investors. However, this is contrasted by a clear negative trend in Foreign Institutional Investor (FII) holding. FIIs have been consistently reducing their stake, with their ownership declining from 7.34% to 1.38%. This divergence between FII and DII sentiment is notable. Despite the FII exit, the strong promoter backing and increasing DII conviction result in an overall good assessment for this category.
| Shareholding (%) | Sep 2024 | Dec 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| FIIs | 7.34% | 6.36% | 5.77% | 1.38% |
| DIIs | 7.53% | 6.99% | 7.39% | 14.36% |
The overall risk profile is high due to severe and persistent financial instability. The primary risk stems from the extreme volatility in core profitability and return metrics, which makes future performance highly unpredictable. The company's earnings have swung between substantial profits and heavy losses, indicating a lack of control over operations. This financial unpredictability is a significant accounting red flag. Furthermore, the company carries a notable level of debt with a deteriorating interest coverage ratio, exposing it to interest rate risk. The consistent selling by Foreign Institutional Investors (FIIs) also signals a perception of heightened risk among international investors. The recurring nature of 'exceptional items' in the profit and loss statement also raises questions about earnings quality.
Accounting quality red flags
There are significant red flags concerning the company's accounting quality and the reliability of its reported earnings. The most prominent issue is the extreme volatility of net profit, which has fluctuated from a profit of ₹123 Cr (2021) to a loss of ₹251 Cr (2022) and then a minimal profit of ₹1 Cr (2024). Such wild swings question the sustainability and quality of earnings. Additionally, the profit and loss statement shows recurring negative 'Exceptional items' (-₹68 Cr in Mar 2023, -₹26 Cr in Mar 2024). When such items appear frequently, they may not be truly 'exceptional' and could be masking underlying operational issues. These factors combined create a high degree of uncertainty around the company's true financial performance.
Foreign exchange or interest rate exposure
The company has a clear and significant exposure to interest rate risk. As of March 2024, the company reported borrowings of ₹565 crore. The risk is amplified by the low Interest Coverage Ratio, which fell to 2.4x in March 2024. A low coverage ratio means that a smaller portion of operating profit is available to cover interest expenses, making the company's earnings more sensitive to any increase in interest rates or a decline in operating profit. A rise in borrowing costs could further strain profitability and cash flows. The provided data does not contain specific information to quantify foreign exchange exposure.
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10601.00Bullish
- SMA 20598.84Bullish
- SMA 50607.87Bearish
- EMA 10601.44Bullish
- EMA 20601.29Bullish
- EMA 50597.27Bullish
- DEMA 10602.78Bullish
- DEMA 20600.70Bullish
- DEMA 50610.25Bearish
- TEMA 10604.69Bullish
- TEMA 20599.85Bullish
- TEMA 50605.10Bullish
- MACD-0.10Bullish
- ADX17.20Weak Trend
- IndicatorValueSignal
- RSI59.20Neutral
- CCI151.19Overbought
- ROC 91.05Bullish
- ROC 142.78Bullish
- ROC 25-0.41Bearish
- Stoch K79.62Neutral
- Stoch D67.37Neutral
- IndicatorValueSignal
- BB Upper607.69Neutral
- BB Middle598.84Neutral
- BB Lower589.99Neutral
- ATR6.64Low Volatility
- IndicatorValueSignal
- MFI68.98Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 2 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10598.98Bullish
- SMA 20604.25Bullish
- SMA 50585.57Bullish
- EMA 10601.46Bullish
- EMA 20600.43Bullish
- EMA 50586.40Bullish
- DEMA 10601.58Bullish
- DEMA 20605.56Bullish
- DEMA 50609.93Bearish
- TEMA 10602.55Bullish
- TEMA 20599.54Bullish
- TEMA 50615.64Bearish
- MACD3.16Bearish
- ADX32.73Strong Trend
- IndicatorValueSignal
- RSI58.98Neutral
- CCI10.11Neutral
- ROC 92.77Bullish
- ROC 140.57Bullish
- ROC 25-0.30Bearish
- Stoch K62.93Neutral
- Stoch D43.90Neutral
- IndicatorValueSignal
- BB Upper624.27Neutral
- BB Middle604.25Neutral
- BB Lower584.22Neutral
- ATR8.95Low Volatility
- IndicatorValueSignal
- MFI44.57Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 4 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10603.87Bullish
- SMA 20593.66Bullish
- SMA 50554.85Bullish
- EMA 10600.57Bullish
- EMA 20591.40Bullish
- EMA 50567.71Bullish
- DEMA 10605.72Bullish
- DEMA 20611.08Bearish
- DEMA 50595.72Bullish
- TEMA 10600.64Bullish
- TEMA 20612.18Bearish
- TEMA 50N/AN/A
- MACD13.78Bearish
- ADX48.05Strong Trend
- IndicatorValueSignal
- RSI62.02Neutral
- CCI35.05Neutral
- ROC 9-2.73Bearish
- ROC 142.61Bullish
- ROC 2513.28Bullish
- Stoch K46.21Neutral
- Stoch D52.67Neutral
- IndicatorValueSignal
- BB Upper645.18Neutral
- BB Middle593.66Neutral
- BB Lower542.14Neutral
- ATR14.00Low Volatility
- IndicatorValueSignal
- MFI78.05Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 33 Technical Indicators From The 1 Day Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
- IndicatorValueSignal
- SMA 10588.15Bullish
- SMA 20559.39Bullish
- SMA 50542.75Bullish
- SMA 100505.49Bullish
- SMA 200476.62Bullish
- EMA 10588.20Bullish
- EMA 20570.46Bullish
- EMA 50543.11Bullish
- EMA 100518.17Bullish
- EMA 200511.99Bullish
- DEMA 10608.39Bearish
- DEMA 20596.17Bullish
- DEMA 50577.09Bullish
- DEMA 100550.22Bullish
- DEMA 200489.79Bullish
- TEMA 10611.07Bearish
- TEMA 20607.50Bearish
- TEMA 50587.85Bullish
- TEMA 100580.72Bullish
- TEMA 200N/AN/A
- MACD20.61Bullish
- ADX27.75Strong Trend
- IndicatorValueSignal
- RSI64.45Neutral
- CCI84.98Neutral
- ROC 1414.72Bullish
- ROC 2511.35Bullish
- Stoch K67.54Neutral
- Stoch D74.04Neutral
- IndicatorValueSignal
- BB Upper630.38Neutral
- BB Middle559.39Neutral
- BB Lower488.39Neutral
- ATR22.66Low Volatility
- IndicatorValueSignal
- MFI81.97Overbought
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 21 Technical Indicators From The 1 Week Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 20506.50Bullish
- SMA 50481.54Bullish
- EMA 20517.20Bullish
- EMA 50514.83Bullish
- DEMA 20549.14Bullish
- DEMA 50N/AN/A
- TEMA 20575.46Bullish
- TEMA 50N/AN/A
- MACD26.16Bullish
- ADX30.26Strong Trend
- IndicatorValueSignal
- RSI64.75Neutral
- CCI211.66Overbought
- ROC 1431.32Bullish
- ROC 2545.81Bullish
- Stoch K79.66Neutral
- Stoch D68.96Neutral
- IndicatorValueSignal
- BB Upper593.41Overbought
- BB Middle506.50Neutral
- BB Lower419.58Neutral
- ATR41.57High Volatility
- IndicatorValueSignal
- MFI71.78Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 25 Technical Indicators From The 1 Month Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
No results for this timeframe
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 6486.50Bullish
- SMA 12483.84Bullish
- SMA 24N/AN/A
- EMA 6499.98Bullish
- EMA 12510.41Bullish
- EMA 24N/AN/A
- DEMA 6512.00Bullish
- DEMA 12N/AN/A
- DEMA 24N/AN/A
- TEMA 6533.85Bearish
- TEMA 12N/AN/A
- TEMA 24N/AN/A
- MACDN/AN/A
- ADXN/AN/A
- IndicatorValueSignal
- RSIN/AN/A
- CCIN/AN/A
- ROC 25N/AN/A
- ROC 50N/AN/A
- Stoch KN/AN/A
- Stoch DN/AN/A
- IndicatorValueSignal
- BB Upper712.93Neutral
- BB Middle524.01Neutral
- BB Lower335.10Neutral
- ATR99.59Low Volatility
- IndicatorValueSignal
- MFI69.50Neutral